Search. Learn. Save

Platform for Pharmaceutical Products for Healthcare Professionals
Search By
☰ Generic Formulas

Generic Formulas X

Amodiaquine

Amodiaquine: A Crucial Antimalarial in the Global Fight Against Malaria

Introduction

Amodiaquine is an important antimalarial drug that has played a critical role in treating and controlling malaria, particularly in regions where Plasmodium falciparum is endemic. Developed as a 4-aminoquinoline compound similar to chloroquine, Amodiaquine has remained relevant even in the face of widespread chloroquine resistance.

1. Overview of Malaria and the Role of Antimalarials

Malaria continues to be a major global health threat, causing an estimated 240 million cases and over 600,000 deaths annually, predominantly in sub-Saharan Africa. The rise of drug resistance has complicated efforts to control the disease, especially against P. falciparum, the most deadly of the five Plasmodium species affecting humans.

Amodiaquine is used primarily in:

  • Treatment of uncomplicated malaria

  • Intermittent preventive treatment in children (IPTc)

  • Seasonal malaria chemoprevention (SMC)

It is often co-formulated with Artemisinin derivatives, particularly Artesunate, due to their synergistic effects and role in combating resistance.

2. Chemical Structure and Classification

  • Chemical class: 4-aminoquinoline

  • IUPAC name: 4-[(7-chloroquinolin-4-yl)amino]-2-[(diethylamino)methyl]phenol

  • Molecular formula: C20H22ClN3O

Structurally, Amodiaquine resembles chloroquine but differs in its pharmacokinetics and metabolic profile, which gives it efficacy against some chloroquine-resistant malaria strains.

3. Mechanism of Action

Amodiaquine works by inhibiting the detoxification of heme, a toxic byproduct generated during hemoglobin digestion by Plasmodium parasites. In the acidic digestive vacuole of the parasite:

  1. Hemoglobin is broken down.

  2. Heme is released, which is toxic to the parasite.

  3. Amodiaquine prevents the polymerization of heme into non-toxic hemozoin.

  4. Free heme accumulates and exerts toxic effects on the parasite, leading to its death.

This mechanism is similar to chloroquine but Amodiaquine has higher accumulation in parasitized cells and may overcome certain resistance mechanisms.

4. Pharmacokinetics

Absorption and Distribution

  • Rapidly absorbed after oral administration

  • Peak plasma concentration: 1–2 hours

  • High volume of distribution due to lipid solubility

Metabolism

  • Metabolized in the liver via CYP2C8 to its active metabolite desethylamodiaquine

  • Desethylamodiaquine has a long half-life (9–18 days), allowing for prolonged antimalarial activity

Excretion

  • Mainly excreted via bile and feces; minor renal elimination

5. Clinical Indications

Monotherapy (historically)

  • Treatment of uncomplicated P. falciparum and P. vivax infections

  • Has largely been replaced by combination therapies due to resistance concerns

Combination Therapy

  • Amodiaquine + Artesunate (ASAQ)

    • WHO-recommended ACT (Artemisinin-based Combination Therapy)

    • High cure rates and reduced risk of resistance development

Preventive Therapy

  • Intermittent Preventive Treatment in Children (IPTc)

    • Reduces malaria incidence and severity

  • Seasonal Malaria Chemoprevention (SMC)

    • Given during peak transmission seasons in endemic regions

    • Usually paired with Sulfadoxine-Pyrimethamine (SP)

6. Efficacy and Resistance

Efficacy

  • Rapid parasite clearance when combined with artemisinin

  • Effective against chloroquine-resistant strains

  • Long half-life of metabolite provides post-treatment prophylaxis

Resistance

  • Resistance to Amodiaquine is less common than chloroquine

  • Resistance typically results from:

    • Mutations in the Pfcrt and Pfmdr1 genes

    • Reduced drug accumulation in the parasite’s digestive vacuole

To delay resistance, WHO recommends Amodiaquine only in combination therapies, especially for P. falciparum.

7. Safety and Side Effects

Common Adverse Effects

  • Gastrointestinal upset (nausea, vomiting, abdominal pain)

  • Headache

  • Dizziness

  • Mild liver enzyme elevation

Serious Adverse Effects (rare but significant)

  • Hepatotoxicity

  • Agranulocytosis

  • Aplastic anemia

These severe effects were primarily noted with long-term or repeated use, which is why monotherapy with Amodiaquine has been replaced by short-course regimens and combinations.

Contraindications

  • Known hypersensitivity

  • History of hepatic disorders

  • Previous blood dyscrasias

  • Concurrent hepatotoxic drugs

8. Dosage and Administration

Treatment Regimens

  • Adult dosage: ~10 mg/kg once daily for 3 days (in combination with artesunate)

  • Children: Dosage adjusted based on weight

Preventive Use (SMC)

  • Monthly doses during the malaria season

  • Age-appropriate fixed-dose formulations

  • Administered under national malaria control programs

9. WHO Recommendations

WHO includes Amodiaquine in its list of Essential Medicines, especially as a part of:

  • ACTs (e.g., ASAQ)

  • Preventive strategies for children in high-transmission areas

Its role in integrated malaria control strategies is expanding due to its affordability, efficacy, and safety when used appropriately.

10. Global Impact and Public Health Use

Sub-Saharan Africa

  • Widespread use in national malaria treatment guidelines

  • ASAQ used in over 20 countries as a first-line ACT

Seasonal Malaria Chemoprevention

  • Piloted and scaled up in West African nations (e.g., Senegal, Mali, Burkina Faso)

  • Proven to reduce malaria incidence by 75% in children under five

Affordability

  • Low cost of production

  • Often included in global health subsidy programs (e.g., Global Fund, UNICEF)

11. Formulations and Brands

  • Available as tablets and dispersible formulations

  • Fixed-dose combination (ASAQ) is co-formulated for ease of administration

  • Common brands:

    • Coarsucam, ASAQ Winthrop, Arsucam, Amodan

12. Ongoing Research and Future Directions

Triple Combination Therapies

  • Trials underway combining Amodiaquine with Artemether–Lumefantrine or Mefloquine

  • Aim: Counteract emerging resistance to current ACTs

Novel Delivery Methods

  • Long-acting injectables for seasonal protection

  • Pediatric-friendly dispersible tablets

Genetic Markers

  • Research on Pfmdr1 mutations to predict efficacy

  • Development of diagnostic tests to tailor therapy

13. Amodiaquine vs. Chloroquine: A Comparative Insight

Parameter Amodiaquine Chloroquine
Efficacy against resistant strains Higher Low
Side effects Rare hepatotoxicity, agranulocytosis Retinopathy, pruritus
Half-life of active metabolite Longer Moderate
Use in preventive therapy Common Rare
WHO recommendation Yes (in ACTs) No longer preferred for P. falciparum

14. Regulatory Status

  • WHO-approved in fixed-dose ACTs

  • Prequalified by WHO in multiple generic versions

  • Included in national malaria treatment policies in:

    • Nigeria

    • Ghana

    • Cameroon

    • Burkina Faso

    • Senegal

15. Storage and Stability

  • Stable at room temperature

  • Should be stored in airtight, light-resistant containers

  • Shelf life typically 3–5 years, depending on the formulation

16. Patient Counseling Tips

  • Take with food to reduce stomach upset

  • Complete the full course even if symptoms resolve

  • Watch for signs of jaundice, fatigue, or dark urine

  • Report any signs of bleeding or infection

  • Do not reuse leftover doses for future fever episodes

Conclusion

Amodiaquine continues to be a valuable tool in the global arsenal against malaria, especially when used in combination therapies. Its strong efficacy, low cost, and inclusion in WHO-endorsed programs make it indispensable, particularly in resource-limited settings. Despite its potential for rare serious side effects, careful use in short-course regimens has made it both safe and effective. With ongoing innovations and surveillance efforts, Amodiaquine is likely to remain relevant in the fight against malaria for years to come.